NewsFlash »

Bafetinib May Prevent Bone Loss For Cancer Patients – A series of preclinical studies indicate that the drug bafetinib (INNO-406) inhibits bone deterioration in cancer patients who are at high risk for bone loss, including multiple myeloma patients. Although bafetinib is being developed by CytRX for the treatment of certain types of leukemia, the latest preclinical studies showed that bafetinib also suppresses the activity of bone cells that break down bone and cause fractures, bone pain, and high blood calcium levels. Bafetinib is also being tested in ongoing clinical trials for effectiveness against prostate cancer and brain tumors.  For more information, please see the CytRx Corporation press release.

Phase 2 Study Will Examine Curcumin’s Ability To Reduce Myeloma Symptoms During Maintenance Therapy – M.D. Anderson Cancer Center in Houston will begin a Phase 2 clinical trial to determine whether curcumin, the active ingredient in the Indian spice turmeric, can reduce symptoms of myeloma for patients taking Revlimid (lenalidomide) as maintenance therapy. Researchers will assess the effects of curcumin on pain, fatigue, bone aches, numbness, and disturbed sleep. The trial, which is not yet enrolling patients, will begin in June and include approximately 70 participants. For more information, please see the United States Clinical Trials Registry.

MMRF Patient Symposium To Be Held In Los Angeles – The Multiple Myeloma Research Foundation (MMRF) will hold a symposium for myeloma patients and their families on February 26 at Intercontinental Los Angeles Century City. After a basic introduction to multiple myeloma, leading myeloma experts will speak about managing bone disease, treatment options for myeloma patients, and clinical trials. A panel of myeloma experts will also be available to answer questions from patients and family members. Registration will begin at 8:30 a.m., and the program will conclude at 2:30 p.m. For more information or to register, please visit the MMRF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.